Acceptability of clofazimine capsules in children and adolescents with rifampicin-resistant TB

Int J Tuberc Lung Dis. 2024 May 1;28(5):256-258. doi: 10.5588/ijtld.23.0517.

Authors

D T Wademan¹, Z Saule¹, A Marthinus¹, L Viljoen¹, E Nortier¹, J Hughes¹, I Courtney¹, M Palmer¹, A J Garcia-Prats², A C Hesseling¹, G Hoddinott²

Affiliations

¹ Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
² Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa;, University of Wisconsin-Madison, School of Medicine and Public Health, Department of Pediatrics, Madison, WI, USA.

PMID: 38659140
DOI: 10.5588/ijtld.23.0517

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antitubercular Agents / administration & dosage
Capsules
Child
Clofazimine* / administration & dosage
Clofazimine* / therapeutic use
Female
Humans
Male
Rifampin* / administration & dosage
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Rifampin
Clofazimine
Capsules
Antitubercular Agents